Inhibikase Therapeutics, Inc.
IKT
$2.40
$0.041.70%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 0.00 | 79.60K | 196.00K | 260.50K | 324.10K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 0.00 | 79.60K | 196.00K | 260.50K | 324.10K |
| Cost of Revenue | 13.02M | 12.06M | 13.52M | 13.62M | 13.67M |
| Gross Profit | -13.02M | -11.98M | -13.32M | -13.36M | -13.35M |
| SG&A Expenses | 7.04M | 7.03M | 6.84M | 6.73M | 6.68M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 20.06M | 19.08M | 20.35M | 20.35M | 20.35M |
| Operating Income | -20.06M | -19.01M | -20.16M | -20.09M | -20.02M |
| Income Before Tax | -19.57M | -18.38M | -19.20M | -19.03M | -19.13M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -19.57 | -18.38 | -19.20 | -19.03 | -19.13 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -19.57M | -18.38M | -19.20M | -19.03M | -19.13M |
| EBIT | -20.06M | -19.01M | -20.16M | -20.09M | -20.02M |
| EBITDA | -20.04M | -18.98M | -19.98M | -19.91M | -19.85M |
| EPS Basic | -2.72 | -2.82 | -3.10 | -3.34 | -3.67 |
| Normalized Basic EPS | -1.70 | -1.76 | -1.93 | -2.09 | -2.30 |
| EPS Diluted | -2.72 | -2.82 | -3.10 | -3.34 | -3.67 |
| Normalized Diluted EPS | -1.70 | -1.76 | -1.93 | -2.09 | -2.30 |
| Average Basic Shares Outstanding | 28.91M | 26.19M | 24.82M | 23.06M | 21.13M |
| Average Diluted Shares Outstanding | 28.91M | 26.19M | 24.82M | 23.06M | 21.13M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
